Diagnostyka

Diagnostyka FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Diagnostyka (DIA.WA) as of Oct 27, 2026 is 137.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 126.59 % — a change of 8.94% (higher).

FCF Conversion

137.91 %

YoY

8.94%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Diagnostyka is 2025 137.91 % . FCF Conversion Rate (FCF/EBITDA) of Diagnostyka was 2024 126.59 % . It decreases by 8.94% higher compared to the previous year.

The Diagnostyka FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
108.81 PLN
Jan 1, 2022
116.19 PLN
Jan 1, 2023
206.32 PLN
Jan 1, 2024
126.59 PLN
Jan 1, 2025
137.91 PLN
The Diagnostyka FCF Conversion history
YEARFCF ConversionYoY
137.91 %+8.94%
126.59 %-38.64%
206.32 %+77.57%
116.19 %+6.78%
108.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnostyka Stock analysis

What does Diagnostyka do? Diagnostyka SA generates revenue through its network of 180 laboratories and 1,100 Sampling Labs across Poland, offering over 3,000 test types including hematology, infection diagnostics, allergology, and hormonal diagnostics. The company provides both routine and specialist laboratory services, with tests available with or without a physician's referral, catering to individual patients and healthcare providers. Its specialization in molecular biology, autoimmune diagnostics, and blood collection drives demand from private individuals seeking direct access to medical analysis without a doctor's prescription. The firm's revenue model relies on a comprehensive service chain from biological material collection and transportation to final analysis results, serving a broad customer base including patients, clinics, and hospitals. With a focus on accessible diagnostics, Diagnostyka SA expands its market reach through its extensive lab network, enabling widespread availability of medical testing services throughout Poland. The company's ability to deliver specialized tests like molecular biology and autoimmune diagnostics differentiates its offerings in the healthcare sector. Diagnostyka is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnostyka stock

FCF Conversion Rate (FCF/EBITDA) of Diagnostyka is 137.91 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Diagnostyka changed from 126.59 % to 137.91 %, representing a 8.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Diagnostyka since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Diagnostyka with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Diagnostyka

All Key Metrics — Diagnostyka